The Column Group Research
Investment Thesis
The Column Group (TCG) is a science-driven venture ecosystem dedicated to fueling scientific innovation in the life sciences industry. Founded in 2007 by Peter Svennilson, TCG's core belief is that transformative therapeutics come from partnering deeply with elite academic scientists and industry operators from the earliest moment of company formation, not from writing checks into companies that already exist. The firm calls this an "edge-to-edge investment model" — it aims to support a company from inception (often co-founding it around a scientist's discovery) all the way through clinical development, public listing, and ultimately exit or acquisition.
TCG is structurally unusual among biotech VCs in that it operates a full ecosystem of complementary funds rather than a single vehicle: Platform and Opportunity funds for early-stage, platform-based company creation; TCG Labs-Soleil, a dedicated "venture-biotech" model that pairs a venture fund with an in-house R&D hub (Soleil) to build single-asset biologic programs from scratch; and TCG Crossover (TCGX), which invests later-stage private and public capital into companies as they approach or cross the public markets. This lets TCG participate in a company's full lifecycle under one roof rather than handing off to different investors at each stage.
Sector Focus
TCG invests exclusively in biotechnology and life sciences, with particular strength in:
- Drug discovery platforms built around novel biology (structural biology, chemical proteomics, RNA processing, epitranscriptomics)
- Single-asset biologic and small-molecule programs advanced through TCG Labs-Soleil
- Oncology, immunology/inflammation, neuroscience/neurodegeneration, and rare disease
- Later-stage and crossover investments in public or soon-to-be-public biotech companies via TCGX
Stage Focus
TCG spans the full biotech lifecycle: company creation and early-stage drug discovery (via Platform/Opportunity funds and Labs-Soleil), through Series A/B financings, to later-stage private and public crossover investing (via TCGX). It is unusually willing to be the founding investor of a company built around a single scientific insight.
Check Size
TCG does not publish a standard check size. Recent portfolio company rounds it has led or co-led range widely by stage and asset maturity — from tens of millions in early single-asset financings up to $150M+ Series B rounds for pivotal-stage assets (e.g., Vaderis Therapeutics' $152.5M Series B, InduPro's $77M Series B). Crossover rounds via TCGX can run into the hundreds of millions.
Lead Tendency
TCG frequently leads or co-leads rounds, especially where it originated or helped create the company (e.g., InduPro's $77M Series B was led by The Column Group). In syndicated late-stage rounds it often participates alongside other specialist and crossover investors (e.g., Vaderis' Series B was co-led by Goldman Sachs Alternatives and TCGX).
Recent Activity
TCG has been highly active raising new capital and deploying it in 2025-2026:
- TCG Crossover closed an oversubscribed $1.3B TCGX Fund III in October 2025.
- TCG Labs-Soleil raised an additional $400M in July 2025, on top of its inaugural $400M+ raised in 2024, to expand its single-asset company creation model and R&D footprint into China.
- Portfolio financings: Atavistik Bio's $120M Series B (December 2025), Vaderis Therapeutics' $152.5M Series B (August 2026), and InduPro's $77M Series B (August 2026, led by TCG).
- Notable exits: Neurona Therapeutics acquired by UCB for up to $1.15B (April 2026); RAPT Therapeutics acquired by GSK for $2.2B (January 2026).
Portfolio Highlights
TCG has started or invested in 55 companies with 18 exits and roughly $4B in cumulative returns. Marquee exits include Carmot Therapeutics (acquired by Roche, December 2023, ~$2.7B upfront plus milestones), Aragon Pharmaceuticals (acquired by J&J, 2013), Seragon Pharmaceuticals (acquired by Genentech/Roche, 2014), Constellation Pharmaceuticals (acquired by MorphoSys, 2021), Exonics Therapeutics (acquired by Vertex, 2019), and Flexus Biosciences (acquired by Bristol-Myers Squibb, 2015). Active public portfolio companies include ORIC Pharmaceuticals (NASDAQ: ORIC), Tenaya Therapeutics (NASDAQ: TNYA), Arcus Biosciences (NYSE: RCUS), Gritstone Bio (NASDAQ: GRTS), Nurix Therapeutics (NASDAQ: NRIX), and Revolution Medicines (NASDAQ: RVMD). Private highlights include Eikon Therapeutics (single-molecule imaging drug discovery) and Kallyope (gut-brain axis therapeutics).
Team
TCG's team is organized around a distinctive mix of full-time investment partners and a deep bench of academic "Science Partners" and "iPartners," several of whom are Nobel laureates or National Academy of Sciences members:
- Peter Svennilson, Founder & Managing Partner — founded TCG in 2007 after 35+ years in venture capital
- Tim Kutzkey, PhD, Managing Partner — founding CEO of Peloton Therapeutics, Neurona, and Surrozen
- Leon Chen, PhD, Partner — co-founder of KAI Pharmaceuticals (acquired by Amgen)
- Sarah Hymowitz, PhD, Partner — 22 years at Genentech, former VP of Protein Sciences
- James Evangelista, Partner & CFO
- Jeff Goater, Partner — former CEO of Surface Oncology, CFO of Voyager Therapeutics
- Hui Tian, PhD, Partner — founding member of NGM Biopharmaceuticals
- Carla Daniel, Partner & Chief People Officer
- John Josey, PhD, Partner — former CEO/President of Peloton Therapeutics
- Craig Parker, Venture Partner — current CEO of Surrozen
- Arnav Mehta, MD, PhD, Venture Partner — GI oncologist at Massachusetts General Hospital
- Notable Science Partners/iPartners: David V. Goeddel (first Genentech scientist), Robert Tjian (former HHMI President), Roger Perlmutter (former Merck R&D chief, overseeing KEYTRUDA development), Jennifer A. Doudna (2020 Nobel laureate, CRISPR co-inventor), Charles Sawyers, Huda Zoghbi, Vishva Dixit, Helen Hobbs, Charles Zuker, Micha Rapé, Dan Nomura, K. Chris Garcia, Michael Fischbach
Decision Process
TCG operates as a full partnership with a layered structure of Partners, Venture Partners, and Science Partners/iPartners who provide scientific diligence. Given the firm's emphasis on scientist-partnered company creation, investment decisions likely combine full-partnership review with deep input from relevant academic Science Partners on the underlying biology.
Founder Preferences
TCG's model centers on partnering directly with elite academic scientists, often before a company or founding team formally exists — TCG partners themselves frequently step in as founding or interim CEOs (e.g., Tim Kutzkey founding three portfolio companies). This differs from typical VC founder-sourcing and instead reflects deep, long-term relationships with leading academic labs (Berkeley, Stanford, UCSF, MSKCC, Baylor, HHMI-affiliated labs).
Geographic Focus
Headquartered in San Francisco, California, TCG invests primarily in US biotech hubs (SF Bay Area being dominant). TCG Labs-Soleil has expanded its R&D footprint into China as part of its single-asset company-creation model.